BridgeBio Pharma (BBIO) Cash & Current Investments (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Cash & Current Investments data on file, last reported at $940.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 73.92% year-over-year to $940.2 million; the trailing twelve-month figure through Mar 2026 stood at $940.2 million (up 73.92% YoY), and the FY2025 full-year result was $587.5 million, up 63.29% from the prior year.
• Cash & Current Investments improved to $940.2 million in Q1 2026, from $587.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $940.2 million in Q1 2026 to a low of $266.3 million in Q3 2024.
• A 5-year average of $487.5 million and a median of $475.4 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 55.47% in 2022 and jumped 73.92% in 2026, its largest moves.
• Tracing BBIO's Cash & Current Investments over 5 years: stood at $414.6 million in 2022, then decreased by 5.31% to $392.6 million in 2023, then dropped by 8.36% to $359.8 million in 2024, then surged by 63.29% to $587.5 million in 2025, then soared by 60.04% to $940.2 million in 2026.
• Business Quant data shows BBIO's Cash & Current Investments at $940.2 million in Q1 2026, $587.5 million in Q4 2025, and $286.3 million in Q3 2025.